A Novel Nanobody-heavy Chain Antibody Against Angiopoietin-like Protein 3 Reduces Plasma Lipids and Relieves Nonalcoholic Fatty Liver Disease

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2022 May 19

PMID 35590366

Authors

Xiaozhi Hu

Jiajun Fan

Qianqian Ma

Lei Han

Zhonglian Cao

Caili Xu

Jingyun Luan

Guangjun Jing

Yanyang Nan

Tao Wu

Yuting Zhang

Hanqi Wang

Yuanzhen Zhang

Dianwen Ju

Affiliations

Soon will be listed here.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease mainly on account of hypercholesterolemia and may progress to cirrhosis and hepatocellular carcinoma. The discovery of effective therapy for NAFLD is an essential unmet need. Angiopoietin-like protein 3 (ANGPTL3), a critical lipid metabolism regulator, resulted in increased blood lipids and was elevated in NAFLD. Here, we developed a nanobody-heavy chain antibody (VHH-Fc) to inhibit ANGPTL3 for NAFLD treatment.

Results: In this study, we retrieved an anti-ANGPTL3 VHH and Fc fusion protein, C44-Fc, which exhibited high affinities to ANGPTL3 proteins and rescued ANGPLT3-mediated inhibition of lipoprotein lipase (LPL) activity. The C44-Fc bound a distinctive epitope within ANGPTL3 when compared with the approved evinacumab, and showed higher expression yield. Meanwhile, C44-Fc had significant reduction of the triglyceride (~ 44.2%), total cholesterol (~ 36.6%) and LDL-cholesterol (~ 54.4%) in hypercholesterolemic mice and ameliorated hepatic lipid accumulation and liver injury in NAFLD mice model.

Conclusions: We discovered a VHH-Fc fusion protein with high affinity to ANGPTL3, strong stability and also alleviated the progression of NAFLD, which might offer a promising therapy for NAFLD.

Citing Articles

A single-domain antibody library based on a stability-engineered human VH3 scaffold.

Lee N, Jung M, Yang H, Shim H Sci Rep. 2024; 14(1):17747.

PMID: 39085444 PMC: 11291719. DOI: 10.1038/s41598-024-68680-5.

Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4.

Zeng J, Fang Y, Zhang Z, Lv Z, Wang X, Huang Q Oncogene. 2024; 43(29):2244-2252.

PMID: 38806619 PMC: 11245388. DOI: 10.1038/s41388-024-03066-5.

Nanobodies as Diagnostic and Therapeutic Tools for Cardiovascular Diseases (CVDs).

Bocancia-Mateescu L, Stan D, Mirica A, Ghita M, Stan D, Ruta L Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375810 PMC: 10301117. DOI: 10.3390/ph16060863.

Targeting p53 pathways: mechanisms, structures, and advances in therapy.

Wang H, Guo M, Wei H, Chen Y Signal Transduct Target Ther. 2023; 8(1):92.

PMID: 36859359 PMC: 9977964. DOI: 10.1038/s41392-023-01347-1.

Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients.

Naeem M, Bano N, Manzoor S, Ahmad A, Munawar N, Razak S Biomolecules. 2023; 13(1).

PMID: 36671484 PMC: 9855873. DOI: 10.3390/biom13010099.

References

Dewey F, Gusarova V, Dunbar R, ODushlaine C, Schurmann C, Gottesman O . Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017; 377(3):211-221. PMC: 5800308. DOI: 10.1056/NEJMoa1612790. View

Sinha R, Bruinstroop E, Singh B, Yen P . Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists. Thyroid. 2019; 29(9):1173-1191. PMC: 6850905. DOI: 10.1089/thy.2018.0664. View

Pothin E, Lesuisse D, Lafaye P . Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR. Pharmaceutics. 2020; 12(10). PMC: 7601373. DOI: 10.3390/pharmaceutics12100937. View

Barchetta I, Cimini F, Chiappetta C, Bertoccini L, Ceccarelli V, Capoccia D . Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. Liver Int. 2020; 40(9):2139-2147. DOI: 10.1111/liv.14554. View

Inaba T, Matsuda M, Shimamura M, Takei N, Terasaka N, Ando Y . Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J Biol Chem. 2003; 278(24):21344-51. DOI: 10.1074/jbc.M213202200. View

Jin M, Meng F, Yang W, Liang L, Wang H, Fu Z . Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis. J Cardiovasc Pharmacol. 2021; 78(3):394-402. DOI: 10.1097/FJC.0000000000001073. View

Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K . Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021; 74(4):1809-1824. DOI: 10.1002/hep.31843. View

Hegele R . Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet. 2009; 10(2):109-21. DOI: 10.1038/nrg2481. View

Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P . Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 2006; 54(6):1856-66. DOI: 10.1002/art.21827. View

10.

Vermersch E, Jouve C, Hulot J . CRISPR/Cas9 gene-editing strategies in cardiovascular cells. Cardiovasc Res. 2019; 116(5):894-907. DOI: 10.1093/cvr/cvz250. View

11.

Li W, Liu J, Cai J, Zhang X, Zhang P, She Z . NAFLD as a continuous driver in the whole spectrum of vascular disease. J Mol Cell Cardiol. 2021; 163:118-132. DOI: 10.1016/j.yjmcc.2021.10.007. View

12.

Samuel V, Shulman G . Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. Cell Metab. 2017; 27(1):22-41. PMC: 5762395. DOI: 10.1016/j.cmet.2017.08.002. View

13.

Stocki P, Szary J, Rasmussen C, Demydchuk M, Northall L, Logan D . Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin receptor 1. FASEB J. 2020; 35(2):e21172. DOI: 10.1096/fj.202001787R. View

14.

Kaplan R, Zhang T, Hernandez M, Gan F, Wright S, Waters M . Regulation of the angiopoietin-like protein 3 gene by LXR. J Lipid Res. 2003; 44(1):136-43. DOI: 10.1194/jlr.m200367-jlr200. View

15.

Tu L, Showalter M, cajka T, Fan S, Pillai V, Fiehn O . Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. Sci Rep. 2017; 7(1):6120. PMC: 5522413. DOI: 10.1038/s41598-017-05040-6. View

16.

HAMERS-CASTERMAN C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E . Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428):446-8. DOI: 10.1038/363446a0. View

17.

Vincke C, Gutierrez C, Wernery U, Devoogdt N, Hassanzadeh-Ghassabeh G, Muyldermans S . Generation of single domain antibody fragments derived from camelids and generation of manifold constructs. Methods Mol Biol. 2012; 907:145-76. DOI: 10.1007/978-1-61779-974-7_8. View

18.

Romeo S, Yin W, Kozlitina J, Pennacchio L, Boerwinkle E, Hobbs H . Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2008; 119(1):70-9. PMC: 2613476. DOI: 10.1172/JCI37118. View

19.

Eslam M, Valenti L, Romeo S . Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2017; 68(2):268-279. DOI: 10.1016/j.jhep.2017.09.003. View

20.

Li X, Wang M, Zhang X, Liu C, Xiang H, Huang M . The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats. Clin Transl Med. 2020; 9(1):16. PMC: 7018876. DOI: 10.1186/s40169-020-0265-2. View